New drug combo aims to save wombs in young women with uterine cancer
NCT ID NCT06914297
First seen Jun 06, 2026 · Last updated Jun 16, 2026 · Updated 2 times
Summary
This study tests a combination of an immune-boosting drug (TQB2450) and a high-dose hormone (progestin) to treat young women (ages 18-45) with a specific type of early-stage endometrial cancer (MMRd). The goal is to eliminate the cancer while preserving the uterus so patients can still have children. Ten participants will receive the treatment and be monitored every 12 weeks to see if the cancer disappears and how long it stays away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tenth People's Hospital of Tongji University
RECRUITINGShanghai, Shanghai Municipality, 200072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.